Pathomorphological characteristics of bisphosphonate osteonecrosis of the jaws
- 作者: Spevak E.M.1, Christoforando D.Y.1
-
隶属关系:
- «Stavropol state medical University» Ministry of healthcare of the Russian Federation
- 期: 卷 20, 编号 5 (2016)
- 页面: 273-276
- 栏目: Articles
- URL: https://ogarev-online.ru/1728-2802/article/view/42097
- DOI: https://doi.org/10.18821/1728-28022016;20(5):273-276
- ID: 42097
如何引用文章
全文:
详细
作者简介
Elena Spevak
«Stavropol state medical University» Ministry of healthcare of the Russian Federation
Email: cymbal.elena@mail.ru
post-graduate student of the Department of Operative Dentistry and Maxillofacial Surgery «Stavropol State Medical University» 355017, Stavropol
D. Christoforando
«Stavropol state medical University» Ministry of healthcare of the Russian Federation355017, Stavropol
参考
- Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B. et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg. 2014; 72(10): 1938-56.
- Khosla S., Burr D., Cauley J., Cauley J., Dempster D.W., Ebeling P.R., Felsenberget D. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2007; 22: 1479-91.
- Marx R.E. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 2003; 61: 1115-7.
- Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G. et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J. Clin. Oncol. 2005; 23: 8580.
- Dimopoulos M., Kastritis E., Anagnostopoulos A., Melakopoulos I., Gika D., Moulopoulos L.A. et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006; 91: 968.
- Bantis A., Zissimopoulos A., Sountoulides P., Bantis A., Zissimopoulos A., Sountoulides P. et al. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies. Tumori. 2011; 97: 479-83.
- Tennis P., Rothman K.J., Bohn R.L., Tan H., Zavras A., Laskarides C. et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol. Drug Saf. 2012; 21: 810-7.
- Жабина А.С. Роль бисфосфонатов для профилактики и лечения метастазов в кости. Практ. онкол. 2011; 12(3): 124-31.
- Сулейманов А.М. Бисфосфонатные остеонекрозы челюстей. Медицинский. вестник Башкортостана. 2012; 7(2): 112-5.
- Тарасенко С.В., Дробышев А.Ю., Шипкова Т.П., Жукова Н.А. и др. Тактика лечения больных с бисфосфонатным остеонекрозом челюстей. Российская стоматология. 2012; (2): 3-13.
- Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 2015; 30(1): 3-23. doi: 10.1002/jbmr.2405.
- Заславская Н.А., Дробышев А.Ю., Волков А.Г., Лежнев Д.А. Диагностика и лечение остеонекрозов челюстей у больных злокачественными новообразованиями, получающих терапию антирезорбтивными препаратами (бисфосфонаты, деносумаб). Медицинский вестник МВД. 2014; 68(1): 14-6.
补充文件
